Relapse of chronic phase chronic myeloid leukemia (CML) on imatinib: BCR-ABL kinase domain mutations conferring drug resistance are frequently detectable prior to clinical evidence of relapse.

被引：0
|
作者：
Shah, NP [1 ]
Nicoll, JM [1 ]
Paquette, RL [1 ]
Sawyers, CL [1 ]
机构：
[1] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, David Geffen Sch Med, Dept Med,Div Hematol Oncol, Los Angeles, CA 90024 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1418
引用
收藏
页码：366A / 366A
页数：1
相关论文
共 50 条
  • [1] In chronic myeloid leukemia (CML) patients with complete cytogenctic response to imatinib, BCR-ABL kinase domain mutations are relatively rare and not consistently associated with subsequent relapse.
    Sherbenou, DW
    Wong, MJ
    Humayun, A
    McGreevey, LS
    Yang, R
    Heinrich, MC
    Press, RD
    Druker, BJ
    Deininger, MW
    BLOOD, 2005, 106 (11) : 131A - 131A
  • [2] Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Saffari, Zeinab
    Nadali, Fatemeh
    Ostadali, Mohammadreza
    Ghadimi, Habibeh
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    Rostami, Shahrbano
    HEMATOLOGY, 2013, 18 (06) : 327 - 332
  • [3] Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia
    O'Hare, Thomas
    Eide, Christopher A.
    Deininger, Michael W. N.
    BLOOD, 2007, 110 (07) : 2242 - 2249
  • [4] Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
    Chandrasekhar, Chodimella
    Kumar, Pasupuleti Santhosh
    Sarma, Potukuchi Venkata Gurunadha Krishna
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [5] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [6] BCR-ABL kinase domain mutations in chronic myeloid leukemia - Not quite enough to cause resistance to imatinib therapy?
    Lange, T
    Park, B
    Willis, SG
    Deininger, MWN
    CELL CYCLE, 2005, 4 (12) : 1761 - 1766
  • [7] Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
    Chodimella Chandrasekhar
    Pasupuleti Santhosh Kumar
    Potukuchi Venkata Gurunadha Krishna Sarma
    Scientific Reports, 9
  • [8] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Yuan Wei
    Mats Hardling
    Bob Olsson
    Rahil Hezaveh
    Anne Ricksten
    Dick Stockelberg
    Hans Wadenvik
    Annals of Hematology, 2006, 85 : 841 - 847
  • [9] Not all imatinib resistance in CML are BCR-ABL kinase domain mutations
    Wei, Yuan
    Hardling, Mats
    Olsson, Bob
    Hezaveh, Rahil
    Ricksten, Anne
    Stockelberg, Dick
    Wadenvik, Hans
    ANNALS OF HEMATOLOGY, 2006, 85 (12) : 841 - 847
  • [10] Imatinib resistance in chronic myelogenous leukemia is frequently associated with either ABL kinase mutations or with secondary rearrangements of the BCR-ABL
    Yin, C
    Luthra, R
    Cortes, J
    Reeves, N
    Hayes, K
    Glassman, A
    Kantarjian, H
    Jones, D
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2004, 6 (04): : 416 - 416
12345